BeiGene
BGNE
$179.87
Share price
-2.33%
Change (1 day)
5.98%
Change (1 year)
Categories
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.
BeiGene (BGNE) - Net assets
Net assets on the balance sheet as of June 2023 : $3.79 B
According to BeiGene
's latest financial reports the company has $3.79 B in net assets.
A company’s net assets is the sum of its assets minus the sum of its liabilities.
BeiGene - Net assets on balance sheet (from 2014 to 2023)
Net assets by year
| Year | Net assets | Change |
|---|---|---|
| 2022-12-31 | $4.38 B | -29.79% |
| 2021-12-31 | $6.24 B | 61.35% |
| 2020-12-31 | $3.86 B | 295.48% |
| 2019-12-31 | $0.97 B | -44.21% |
| 2018-12-31 | $1.75 B | 156.29% |
| 2017-12-31 | $0.68 B | |
| 2016-12-31 | $N/A | |
| 2015-12-31 | $N/A | -100% |
| 2014-12-31 | $25.76 M | -166.54% |
| 2013-12-31 | $-38.73 M |
Net assets for similar companies or competitors
| Company | Net assets | differencediff. | Country |
|---|---|---|---|
 OPKO Health
OPK | $1.53 B | -59.58% | 🇺🇸 USA |
 Onconova Therapeutics ONTX | $18.89 M | -99.50% | 🇺🇸 USA |